Exco InTouch Successfully Completes HIPAA Security Audit
News Jan 22, 2014
Exco InTouch has announced that it has successfully undergone and completed an independent audit to assess compliance utilizing the National Institute of Standards and Technology (NIST) guidelines for Health Insurance Portability and Accountability Act (HIPAA) security.
HIPAA rules constitute a set of regulations from the US Department of Health & Human Services relating to any Protected Health Information (PHI) that identifies health or financial data of US citizens stored on computer systems.
The Security Rule specifies a series of administrative, physical, and technical safeguards for covered entities and their business associates to use to assure the confidentiality, integrity, and availability of electronic PHI.
Dale Jessop, Chief Technology Officer at Exco InTouch commented “Security of data and the protection of personal information remain the highest priority for Exco InTouch. Whilst no formal certification for HIPAA exists, to be independently audited against NIST guidelines for HIPAA security provides further reassurance to our customers that Exco InTouch business operations are aligned to comply with HIPAA standards.”
Tim Davis, CEO and co-founder of Exco InTouch added “I am extremely proud of the team involved throughout the audit process, and also that of the 64 HIPAA citations we were audited on, no findings were reported".
As a result of this audit, Exco InTouch customers (for whom the company provides mobile and digital patient engagement solutions), can continue to be assured that their programs comply with these stringent security safeguards.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE